Vimoj J Nair1, Robert MacRae1, Abby Sirisegaram2, Jason R Pantarotto3. 1. Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 2. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. 3. Division of Radiation Oncology, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address: jpantarotto@toh.on.ca.
Abstract
PURPOSE: The aim of this study was to determine whether the preradiation maximum standardized uptake value (SUVmax) of the primary tumor for [(18)F]-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) has a prognostic significance in patients with Stage T1 or T2N0 non-small cell lung cancer (NSCLC) treated with curative radiation therapy, whether conventional or stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Between January 2007 and December 2011, a total of 163 patients (180 tumors) with medically inoperable histologically proven Stage T1 or T2N0 NSCLC and treated with radiation therapy (both conventional and SBRT) were entered in a research ethics board approved database. All patients received pretreatment FDG-PET / computed tomography (CT) at 1 institution with consistent acquisition technique. The medical records and radiologic images of these patients were analyzed. RESULTS: The overall survival at 2 years and 3 years for the whole group was 76% and 67%, respectively. The mean and median SUVmax were 8.1 and 7, respectively. Progression-free survival at 2 years with SUVmax <7 was better than that of the patients with tumor SUVmax ≥7 (67% vs 51%; P=.0096). Tumors with SUVmax ≥7 were associated with a worse regional recurrence-free survival and distant metastasis-free survival. In the multivariate analysis, SUVmax ≥7 was an independent prognostic factor for distant metastasis-free survival. CONCLUSION: In early-stage NSCLC managed with radiation alone, patients with SUVmax ≥7 on FDG-PET / CT scan have poorer outcomes and high risk of progression, possibly because of aggressive biology. There is a potential role for adjuvant therapies for these high-risk patients with intent to improve outcomes.
PURPOSE: The aim of this study was to determine whether the preradiation maximum standardized uptake value (SUVmax) of the primary tumor for [(18)F]-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) has a prognostic significance in patients with Stage T1 or T2N0 non-small cell lung cancer (NSCLC) treated with curative radiation therapy, whether conventional or stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Between January 2007 and December 2011, a total of 163 patients (180 tumors) with medically inoperable histologically proven Stage T1 or T2N0 NSCLC and treated with radiation therapy (both conventional and SBRT) were entered in a research ethics board approved database. All patients received pretreatment FDG-PET / computed tomography (CT) at 1 institution with consistent acquisition technique. The medical records and radiologic images of these patients were analyzed. RESULTS: The overall survival at 2 years and 3 years for the whole group was 76% and 67%, respectively. The mean and median SUVmax were 8.1 and 7, respectively. Progression-free survival at 2 years with SUVmax <7 was better than that of the patients with tumor SUVmax ≥7 (67% vs 51%; P=.0096). Tumors with SUVmax ≥7 were associated with a worse regional recurrence-free survival and distant metastasis-free survival. In the multivariate analysis, SUVmax ≥7 was an independent prognostic factor for distant metastasis-free survival. CONCLUSION: In early-stage NSCLC managed with radiation alone, patients with SUVmax ≥7 on FDG-PET / CT scan have poorer outcomes and high risk of progression, possibly because of aggressive biology. There is a potential role for adjuvant therapies for these high-risk patients with intent to improve outcomes.
Authors: Zachary A Kohutek; Abraham J Wu; Zhigang Zhang; Amanda Foster; Shaun U Din; Ellen D Yorke; Robert Downey; Kenneth E Rosenzweig; Wolfgang A Weber; Andreas Rimner Journal: Lung Cancer Date: 2015-05-28 Impact factor: 5.705
Authors: Chunyan Duan; W Art Chaovalitwongse; Fangyun Bai; Daniel S Hippe; Shouyi Wang; Phawis Thammasorn; Larry A Pierce; Xiao Liu; Jianxin You; Robert S Miyaoka; Hubert J Vesselle; Paul E Kinahan; Ramesh Rengan; Jing Zeng; Stephen R Bowen Journal: Phys Med Biol Date: 2020-10-07 Impact factor: 3.609
Authors: Turki M Almuhaimid; Won Sub Lim; Jong-Lyel Roh; Jungsu S Oh; Jae Seung Kim; Soo-Jong Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim Journal: J Cancer Res Clin Oncol Date: 2018-10-06 Impact factor: 4.553
Authors: Jia Wu; Todd Aguilera; David Shultz; Madhu Gudur; Daniel L Rubin; Billy W Loo; Maximilian Diehn; Ruijiang Li Journal: Radiology Date: 2016-04-05 Impact factor: 11.105
Authors: Jia Wu; Michael F Gensheimer; Xinzhe Dong; Daniel L Rubin; Sandy Napel; Maximilian Diehn; Billy W Loo; Ruijiang Li Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-24 Impact factor: 7.038
Authors: Ivayla Apostolova; Julian Rogasch; Ralph Buchert; Heinz Wertzel; H Jost Achenbach; Jens Schreiber; Sandra Riedel; Christian Furth; Alexandr Lougovski; Georg Schramm; Frank Hofheinz; Holger Amthauer; Ingo G Steffen Journal: BMC Cancer Date: 2014-12-01 Impact factor: 4.430
Authors: Corey J Hobbs; Stephen J Ko; Nitesh N Paryani; Joseph M Accurso; Kenneth R Olivier; Yolanda I Garces; Sean S Park; Christopher L Hallemeier; Steven E Schild; Sujay A Vora; Jonathan B Ashman; William G Rule; Johnny R Bowers; Michael G Heckman; Nancy N Diehl; Robert C Miller Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2017-12-26